Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma

Fernandez, Eugenio; Cacheux, Wulfran; Frossard, Jean-Louis; Kossler, Thibaud; Abou, Magali; Moniez, Michael; Huber, Olivier; Puppa, Giacomo; Roth, Arnaud

doi:10.1016/j.dld.2016.12.025

Scientific article

English

Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma

ContributorsFernandez, Eugenio; Cacheux, Wulfran; Frossard, Jean-Louis; Kossler, Thibaud; Abou, Magali; Moniez, Michael; Huber, Olivier; Puppa, Giacomo; Roth, Arnaud

Published inDigestive and Liver Disease, vol. 49, no. 5, p. 552-556

Publication date2017

Abstract

Perioperative chemotherapy improves the prognosis of patients with locoregionally advanced resectable gastric and gastro-esophageal junction adenocarcinoma. Nevertheless, only 50% of operated patients could receive the postoperative component chemotherapy. An exclusive preoperative chemotherapy is therefore an interesting strategy. We report the clinical course of patients with operable gastric and gastroesophageal junction adenocarcinoma treated with an intention of exclusive preoperative chemotherapy.

Affiliation

Research group

Citation (ISO format)

FERNANDEZ, Eugenio et al. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma. In: Digestive and Liver Disease, 2017, vol. 49, n° 5, p. 552–556. doi: 10.1016/j.dld.2016.12.025

Article (Published version)

Identifiers

PID : unige:94216
DOI : 10.1016/j.dld.2016.12.025
PMID : 28179095

ISSN of the journal1590-8658

483views

1downloads

Creation05/11/2017 11:55:00 AM

First validation05/11/2017 11:55:00 AM

Update time03/15/2023 1:40:58 AM

Status update03/15/2023 1:40:57 AM

Last indexation01/16/2024 11:56:32 PM

Archive ouverte UNIGE

Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma

Technical informations